Arcadia Biosciences, Inc.
RKDA
$3.60
$0.020.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.17M | 5.41M | 5.26M | 5.05M | 4.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.17M | 5.41M | 5.26M | 5.05M | 4.61M |
| Cost of Revenue | 3.09M | 3.27M | 3.08M | 2.87M | 2.20M |
| Gross Profit | 2.08M | 2.14M | 2.18M | 2.18M | 2.41M |
| SG&A Expenses | 8.08M | 8.75M | 9.31M | 9.63M | 8.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.17M | 12.01M | 12.38M | 12.50M | 10.88M |
| Operating Income | -6.00M | -6.61M | -7.13M | -7.46M | -6.27M |
| Income Before Tax | -5.03M | -7.07M | -762.00K | -4.31M | -724.00K |
| Income Tax Expenses | 8.00K | 8.00K | 8.00K | 8.00K | 7.00K |
| Earnings from Continuing Operations | -5.04 | -7.08 | -0.77 | -4.32 | -0.73 |
| Earnings from Discontinued Operations | -27.00K | -457.00K | -1.25M | -2.72M | -5.10M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 0.00 |
| Net Income | -5.07M | -7.54M | -2.02M | -7.04M | -5.83M |
| EBIT | -6.00M | -6.61M | -7.13M | -7.46M | -6.27M |
| EBITDA | -5.95M | -6.55M | -7.05M | -7.34M | -6.12M |
| EPS Basic | -3.71 | -5.52 | -1.48 | -5.16 | -4.28 |
| Normalized Basic EPS | -3.49 | -4.42 | -2.91 | -3.72 | -2.03 |
| EPS Diluted | -3.72 | -5.52 | -1.93 | -5.61 | -4.73 |
| Normalized Diluted EPS | -2.31 | -3.24 | -2.35 | -3.16 | -1.47 |
| Average Basic Shares Outstanding | 5.47M | 5.46M | 5.46M | 5.45M | 5.45M |
| Average Diluted Shares Outstanding | 6.70M | 6.70M | 7.27M | 7.27M | 7.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |